Reverse Aging Scientist Discovers New Ways to Reverse Aging
People age at different rates. Some stay healthy into their ninth or tenth decade while others develop age-related diseases much sooner.
Researchers are actively working on ways to halt or reverse aging. Dr. Sinclair, an esteemed longevity scientist, recently gave an interview with Peter Diamandis where he predicted we will soon see pills which can significantly rewind time and double lifespans within 10 years.
Dr. Sinclair’s Information Theory of Aging
Information is stored primarily through two distinct channels: the genome is made up of nucleic acid-based genes that act as the foundation; while epigenome consists of chemical modifications to DNA and histone proteins that regulate gene expression patterns and confer specific identities and functions to cells. With age comes epigenetic disarray that leads to loss of youthful information; The Information Theory of Aging (ITOA) suggests this lost data could be recovered via epigenetic reprogramming to revive damaged or aged tissues and reverse signs of aging – potentially catalyzing age reversal!
Sinclair and his team have demonstrated that epigenetic reprogramming using Yamanaka factor genes can revive neurons in older mice, improving vision while increasing lifespan by 40%.
Partial Cellular Reprogramming
Scientists have recently discovered that partially reprogramming cells can rejuvenate and improve physiological conditions both in vitro and in vivo, including DNA methylation and transcription changes caused by cellular senescence. Reprogramming can even reverse aspects such as DNA methylation and transcription changes associated with cell aging – something not fully understood; though OSKM factors appear to activate a “reprogramming network” which alters gene expression while changing chromatin landscape, likely linked with rejuvenation processes; further research must be conducted into how these changes happen and their linkages with rejuvenation processes in order to determine what effects this network may be coupled with rejuvenation processes or not –
Partial reprogramming holds great promise as a treatment option for diseases like diabetes and Alzheimer’s by rejuvenating non-skin cells. Unfortunately, however, the process is complex and requires further study in order to ensure its safety – currently rating an 8/10 difficulty scale in lab environments; even if successful it would likely require insurance coverage to make treatment affordable for most people.
Recent research has demonstrated that 13 days of partial reprogramming is enough to reset epigenetic age markers and restore function in skin cells, as well as pave the way for future research on treating other diseases through partial reprogramming.
Researchers are exploring reprogramming methods and safety concerns, while simultaneously seeking ways to lower costs. If these findings can be transferred into human clinical trials, it could offer an affordable alternative to costly pharmaceutical approaches.
As with any experimental therapy, there are several challenges associated with regenerative medicine that must be surmounted before its commercial release; but scientists remain hopeful that eventually they will be able to use this technique to effectively prevent or treat various age-related diseases.
Shift Bioscience, a new gene-editing company, seeks to reverse aging through genetics, artificial intelligence and cellular reprogramming. They plan to raise funds and conduct human clinical trials by 2020 with investors BGF, Kindred Capital and Jonathan Milner backing this venture. Shift recently concluded its $16 Million Seed Round to speed its development efforts – this money will go toward creating genome editing technologies and reprogramming protocols.
Yamanaka Gene Therapy
After Shinya Yamanaka shared the 2012 Nobel Prize for his groundbreaking discovery of a combination of genes that reprogram somatic cells into embryonic stem cells, researchers have been exploring its use for medical applications. By using harmless viruses to deliver some of the necessary factors for cell reprogramming, scientists can transform mature (differentiated) cells into young (pluripotent) stem cells which can then regain lost functionality caused by injury, disease or ageing.
The Yamanaka factors – Oct4, Sox2, KLF4 and MYC – are essential in reprogramming adult cells back to youth-like DNA expression levels, but prolonged expression of these genes may lead to cancerous tumors or other unwanted side effects that make full cellular reprogramming impractical for clinical applications.
Harvard University researchers developed an effective partial reprogramming approach that bypasses key oncogene c-Myc, and used this method to achieve comparable methylome and transcriptome rejuvenation without pluripotency pathways that raise safety red flags. They demonstrated similar reversals of age-related diseases like eye deterioration and elevated eye pressure among treated mice.
Life Biosciences was the first company to demonstrate that an in vivo partial epigenetic reprogramming therapy could effectively treat glaucoma using modified adeno-associated viruses to deliver genes encoding OCT-4, SOX-2 and KLF-4 (three so-called Yamanosaka factors), which then express into patients’ cells where they restore methylation patterns while rejuvenating cells – this is currently in preclinical trials for their regenerative medicine program.
Scientists continued to enhance the efficiency of partial reprogramming in 2023 by decreasing the number of required factors and shortening their expression duration, as well as better defining metabolic requirements for effective reprogramming – one study revealed that OSKM-induced reprogramming process depletes vitamin B12 levels from target cells; supplementation increased effectiveness.
Artificial Intelligence
Artificial intelligence (AI) refers to a set of techniques designed to mimic human cognitive functions such as perception, planning, reasoning, learning, communicating and decision-making. AI has revolutionized many areas of our lives from autonomous vehicles and customer service chatbots to medical diagnostics; even video game designers use artificial intelligence techniques for more realistic characters and more engaging gameplay.
AI holds great promise to accelerate reverse aging research breakthroughs by making it faster and simpler to identify, validate, and target interventions for biomarkers of aging and interventions that promote longevity. AI tools are being utilized to design drugs targeting multiple biological pathways at once; one study published by Aging Cell used an AI tool that identified drugs capable of significantly prolonging C. elegans lifespan by targeting multiple cell signaling pathways simultaneously.
AI technology also shows great promise when applied to simulating the aging process more accurately. While traditional computer models only predict an average value for each variable, generative modeling uses past data to identify likely values for variables based on historical records. This allows scientists to better simulate aging processes and predict outcomes of interventions more precisely.
Artificial intelligence is being utilized to identify drug candidates that target the 12 purported causes of aging, including senescent cells, mitochondrial dysfunction, telomere shortening, DNA damage, protein degradation, epigenetic changes and neurodegeneration. An anti-ageing medication identified through AI research includes rapamycin which has been proven to extend mice lifespan while delaying age-related diseases onset.
Now, for the first time ever, it is possible to take an holistic approach to healthy longevity by tracking individual biological markers and identifying interventions likely to extend healthspan. Peter Thiel, founder of hedge fund company The Founders Fund, co-founder of Fountain Life and chairman of Hevolution Foundation is deeply invested in using AI as part of healthy longevity research, funding some of the world’s most ambitious healthspan labs.




